Debra Hawes, MD

Director of Pathology Core Lab
Neuropathologist
Attending Physician
Associate Professor of Clinical Pathology, Keck School of Medicine of USC

Dr. Debra Hawes is the Director of Pathology Core Lab at CHLA. She also serves as an Associate Professor of Clinical Pathology at the USC Keck School of Medicine. Her research interests are on biologic markers of disease progression and cancer prevention. She performs manuscript review for multiple oncology-related journals and is central in projects related to cancer progression and therapy.

Education

Medical School

Ross University School of Medicine

Residency

Department of Pathology, LAC+USC Medical Center

Fellowship

Department of Pathology, LAC+USC Medical Center (Surgical Pathology)
Department of Pathology, LAC+USC Medical Center (Gynecologic Pathology)

Accomplishments

Certification

American Board of Pathology: Anatomic Pathology

Memberships

Los Angeles Society of Pathologists
American Association for Cancer Research
Association of Clinical Research Professionals
American Society of Clinical Pathologists

Medical Awards

Dean's List of Outstanding Achievement in the Basic Sciences, Ross University School of Medicine (1988)
Graduated with High Honors, Ross University School of Medicine (1991)

Publications

Publications

Chung* K, Hovanessian-Larsen* LJ, Hawes* D, Taylor D, Downey S, Spicer DV, Stanczyk FZ, Patel S, Anderson AR, Pike MC, Wu AH, Pearce CL. Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation. Breast Cancer Res Treat 132(2):653-60, 2012 (*co-first authors). UI 22083231
Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH, Pike MC, Pearce CL. Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception 86(3):238-43, 2012 UI 22325110
Mitra AP, Castelao JE, Hawes D Tsao-Wei DD, Jiang X, Shi SR, Datar RH, Skinner EC, Stein JP, Groshen S, Yu MC, Skinner DG, Cortessis VK, Cote RJ. Cancer 119(4):756-65, 2013 UI 23319010
Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge N-O, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B. Differential effects of RUNX2 on androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Res; 74(10): 2857-68, 2014 doi; 10.1158/0008-5472
Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Hawes D, Schally A, Pinski J. Phase I dose escalation study of the targeted cytotoxic LH-RH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clin Cancer Res 20(24):6277-83, 2014 doi 10.1158/1078-04326277

Research

Research Summary

Biological markers of disease progression; cancer prevention